This single-center retrospective analysis evaluated the clinical value of adding a tumor-bed boost to postoperative radiotherapy in younger women with invasive ductal carcinoma treated by breast-conserving surgery. The specific question was whether a 10 Gy boost to the tumor bed, delivered in the modern, risk-adapted radiotherapy era, improves local control and survival in female patients aged 50 years or younger who had widely negative surgical margins (>5 mm) after BCS.
The investigators framed the study to determine if routine boost irradiation remains necessary for carefully selected low-risk patients in whom margin-negative resection has already been achieved.
This retrospective study included 318 female patients aged ≤50 years with pathologically confirmed invasive ductal carcinoma (IDC) and negative surgical margins (>5 mm) who underwent breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) at Tohoku University Hospital between 2008 and 2022.
Treatment allocation reflected institutional practice changes over time: patients treated before 2016 did not receive a tumor-bed boost, whereas patients treated from 2016 onward received a 10 Gy boost to the tumor bed in addition to WBI. A total of 110 patients received boost irradiation and 208 did not.
Outcomes were estimated from the first date of radiotherapy. The primary local endpoint reported was ipsilateral breast tumor recurrence (IBTR); overall survival (OS) was reported as a survival endpoint. Survival estimates were calculated using the Kaplan–Meier method. Additional details such as systemic therapy regimens, radiotherapy fractionation, toxicity assessments, and multivariable adjustments were not reported in the abstract.
Patient and tumor characteristics in the abstract indicate that luminal disease was the predominant subtype in both groups: 87 of 110 in the boost group and 159 of 208 in the non-boost group. Triple-negative disease was uncommon (11/110 in the boost group and 18/208 in the non-boost group). No further subtype breakdowns or additional baseline characteristics were provided in the abstract.
After a median follow-up of 95.5 months, the 7-year IBTR rates were 1.2% in the boost group and 0% in the non-boost group (log-rank p = 0.859). The 7-year overall survival rates were 96.6% in the boost group and 97.9% in the non-boost group (log-rank p = 0.616). The authors report no statistically significant differences between groups for IBTR or OS.
Within this selected cohort of younger women with IDC and widely negative margins, adding a 10 Gy tumor-bed boost to WBI was not associated with improved local control or overall survival after a median follow-up of nearly eight years. The low absolute rates of IBTR in both groups (1.2% and 0% at 7 years) indicate favorable local control in margin-negative patients managed with modern radiotherapy strategies.
Because the institutional practice changed over time (no boost before 2016; routine 10 Gy boost thereafter), the comparison reflects a temporal treatment-policy shift rather than randomized allocation. The abstract does not report on potential confounders, details of systemic therapy, radiation fractionation, toxicity, cosmetic outcomes, or multivariable analyses that could influence recurrence or survival.
The authors interpret the findings as supporting a risk-adapted approach to postoperative radiotherapy in younger patients with IDC and widely negative margins, suggesting routine boost irradiation may not be necessary in carefully selected low-risk patients.
In this retrospective single-center series of women aged ≤50 years with IDC and surgical margins >5 mm after BCS, the addition of a 10 Gy tumor-bed boost did not demonstrate a statistically significant improvement in ipsilateral breast tumor recurrence or overall survival. The data support consideration of omitted boost irradiation in selected low-risk patients within a modern, risk-adapted radiotherapy strategy.
The abstract reports key design elements and primary outcomes but lacks several details needed to fully assess generalizability and applicability: the absence of randomized assignment, limited reporting of baseline characteristics beyond subtype distributions, no reported information on systemic therapies, toxicity, cosmetic outcomes, or multivariable adjustment are important limitations. These unreported items should be sought in the full text before changing clinical practice.
Clinically, for patients ≤50 years with IDC and widely negative margins after BCS, this study suggests that routine delivery of a 10 Gy tumor-bed boost may be unnecessary when patients are carefully selected and managed within contemporary radiotherapy protocols. The findings support individualized, risk-adapted decision-making rather than universal boost application.
Keywords reported in the article abstract: Breast-conserving surgery; boost radiation; invasive ductal carcinoma; surgical margin; younger patients.
Article metadata available in the abstract: single-center retrospective study at Tohoku University Hospital; inclusion years 2008–2022; sample size 318; boost dose 10 Gy applied from 2016 onward; median follow-up 95.5 months; 7-year IBTR 1.2% (boost) vs 0% (no boost), p = 0.859; 7-year OS 96.6% (boost) vs 97.9% (no boost), p = 0.616. Additional methodological and outcome details were not reported in the abstract.